<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03377725</url>
  </required_header>
  <id_info>
    <org_study_id>RuijinH mutant p53 MDS</org_study_id>
    <nct_id>NCT03377725</nct_id>
  </id_info>
  <brief_title>Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)</brief_title>
  <official_title>Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Li Junmin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective,controlled and multi-institution trial.The aim is to identify if using
      decitabine and Arsenic Trioxide(ATO) as the therapy of Myelodysplastic Syndrome(MDS) has
      better relapse free survival and complete response than using decitabine alone.

      TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53
      (mp53)-targeting regimen was clinically established. Particularly, p53 mutation is associated
      with extremely poor prognosis in myelodysplastic syndromes (MDS) and acute myeloid leukemia
      (AML) patients.

      Decitabine (DAC) is a FDA approved drug for MDS treatment. In two independent clinical trials
      reported recently, DNA demethylating drug DAC treatment yielded a surprisingly high rate of
      complete remission (CR) in mp53-harboring AML/MDS patients (Welch, NEJM, 2016; Chang, BJH,
      2017). Notably, all of the mp53-expressing patients in the two clinical studies relapsed
      quickly.

      Arsenic trioxide (ATO) is a FDA approved drug for M3-AML treatment. Despite of the observed
      efficacy in treating non-APL patients, ATO is not yet approved for non-APL cancer treatment.
      ATO plays key role in regulating both wild-type p53 (wtp53) and mp53. Our published and
      unpublished data suggest ATO potentially hijacks nuclear iASPP-mediated STRaND pathway via
      exposing iASPP's RaDAR nuclear import code (Lu, Cancer Cell, 2013; Lu, Cell, 2014; Lu, Nat
      Rev Mol Cell Biol, 2016; Lu, unpublished). Our unpublished data also suggests a key role of
      ATO in regulating mp53 (Lu, The 17th International p53 Workshop, 2017). ATO is widely
      reported to be able to degrade and thus inhibit mp53's oncogenic function (Hamadeh, BBRC,
      1999)(Liu, Blood, 2003). ATO suppressed cancer cell growth by targeting mp53 for degradation
      by Pirh2 degradation pathway (Yang, JBC, 2011; Yan, PLOS one, 2014);

      Here we explore the potential of combination of DAC and ATO in improving the mp53-harboring
      AML/MDS patients' relapse free survival (RFS) and the ability to thoroughly eliminate mp53
      subclone. Basic researches aiming to explore the mechanisms how mp53 cells responds to DAC
      and/or ATO treatment and how mp53 cells develop resistance to DAC and/or ATO will be coupled.
      We designate trials aiming for a better treatment regimen for mp53 patients as
      'PANDA-Trials'.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      300 MDS patients will be recruited for trial. They will be randomly administrated with ATO +
      decitabine (n=200) or decitabine alone (n=100). The RSF, CR ratio, overall survival will be
      compared between the two arms. Importantly, TP53 status will be sequenced and its correlation
      with RSF, CR ratio, overall survival within the two arms will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relapse free survival</measure>
    <time_frame>up to 6-8 months after complete release</time_frame>
    <description>since a patient first being determined as complete release until relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete release</measure>
    <time_frame>2-4 months since the first cycle of treatment</time_frame>
    <description>the percent of patients with complete release in all patients enrolled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>primary estimated for 1year</time_frame>
    <description>from first diagnosed to death whichever the cause is</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>P53 Mutation</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDS patients of the experimental group will be treated with decitabine and arsenic trioxide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controlled group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MDS patients of the controlled group will be treated with decitabine alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>20mg/m^2,d1-5,ivgtt,28days as a duration</description>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_label>Controlled group</arm_group_label>
    <other_name>DNA demethylation agent</other_name>
    <other_name>DNA damaging agent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>0.16mg/kg,d1-5,ivgtt,28days as a duration</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>As2O3</other_name>
    <other_name>Arsenic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  de novo MDS

          -  The Revised International Prognostic Scoring System(IPSS-R) is intermediate,poor or
             very poor

          -  18-75years old(including 18-year-old and 75-year-old patients)

          -  ECOG＜3,CCI≤1,ADL≥100

          -  bone marrow is active

          -  normal hepatic function and renal function

          -  normal cardiac function

          -  obtain informed consent

        Exclusion Criteria:

          -  previously treated MDS patients

          -  abnormal hepatic function or renal function

          -  severe cardiac disease,including myocardial infarction,cardiac dysfunction

          -  ECG:QTc＞0.44 sec in men,QTc＞0.46 sec in women

          -  with other malignant tumor meanwhile

          -  active tuberculosis or HIV-positive patients

          -  woman who are pregnant or breastfeeding

          -  allergic to any drug in protocol or with contraindications

          -  hypomethylation agent(HMA) is contraindicated

          -  ECOG≥3,CCI＞1,ADL＜100

          -  cannot understand or obey the protocol

          -  with a history of allergies or intolerability

          -  with a history of decitabine therapy

          -  participate in other clinical trials meanwhile

          -  any situations that hinder trial existed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Sujiang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Ruijin Hospital North</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lu Min</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai institute of Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Junmin</last_name>
    <phone>86-13817712211</phone>
    <email>drlijunmin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ruijin Hospital North</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sujiang Zhang, MD</last_name>
      <phone>0086-21-67888761</phone>
      <email>zbruce.zhang@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Sujiang Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junmin Li, MD</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>665251</phone_ext>
      <email>drlijunming@126.com</email>
    </contact>
    <investigator>
      <last_name>Junming Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai Institute of Hematology</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min Lu, Ph.D.</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>610805</phone_ext>
      <email>min.lu@shsmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Min Lu, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chang CK, Zhao YS, Xu F, Guo J, Zhang Z, He Q, Wu D, Wu LY, Su JY, Song LX, Xiao C, Li X. TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes. Br J Haematol. 2017 Feb;176(4):600-608. doi: 10.1111/bjh.14455. Epub 2016 Dec 16.</citation>
    <PMID>27984642</PMID>
  </reference>
  <reference>
    <citation>Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.</citation>
    <PMID>27959731</PMID>
  </reference>
  <reference>
    <citation>Lu M, Breyssens H, Salter V, Zhong S, Hu Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, Knapp S, Kessler BM, Middleton MR, Siebold C, Jones EY, Sviderskaya EV, Cebon J, John T, Caballero OL, Goding CR, Lu X. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell. 2013 May 13;23(5):618-33. doi: 10.1016/j.ccr.2013.03.013. Epub 2013 Apr 25. Erratum in: Cancer Cell. 2016 Nov 14;30(5):822-823.</citation>
    <PMID>23623661</PMID>
  </reference>
  <reference>
    <citation>Lu M, Muers MR, Lu X. Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. Nat Rev Mol Cell Biol. 2016 Aug;17(8):523-32. doi: 10.1038/nrm.2016.41. Epub 2016 May 25. Review.</citation>
    <PMID>27220640</PMID>
  </reference>
  <reference>
    <citation>Lu M, Zak J, Chen S, Sanchez-Pulido L, Severson DT, Endicott J, Ponting CP, Schofield CJ, Lu X. A code for RanGDP binding in ankyrin repeats defines a nuclear import pathway. Cell. 2014 May 22;157(5):1130-45. doi: 10.1016/j.cell.2014.05.006.</citation>
    <PMID>24855949</PMID>
  </reference>
  <reference>
    <citation>Yan W, Jung YS, Zhang Y, Chen X. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase. PLoS One. 2014 Aug 12;9(8):e103497. doi: 10.1371/journal.pone.0103497. eCollection 2014.</citation>
    <PMID>25116336</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Li Junmin</investigator_full_name>
    <investigator_title>director of the hematology department</investigator_title>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Decitabine</keyword>
  <keyword>Arsenic Trioxide</keyword>
  <keyword>P53 Mutations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

